Eli Lilly and Company (SWX:LLY)
Switzerland · Delayed Price · Currency is CHF | Market Cap | 763.35B |
| Revenue (ttm) | 47.38B |
| Net Income (ttm) | 14.68B |
| Shares Out | n/a |
| EPS (ttm) | 16.30 |
| PE Ratio | 51.99 |
| Forward PE | 33.62 |
| Dividend | 5.01 (0.57%) |
| Ex-Dividend Date | Nov 14, 2025 |
| Volume | n/a |
| Average Volume | 1 |
| Open | n/a |
| Previous Close | 880.00 |
| Day's Range | n/a |
| 52-Week Range | 538.08 - 880.00 |
| Beta | 0.33 |
| RSI | 63.29 |
| Earnings Date | Feb 6, 2026 |
About Eli Lilly and Company
Eli Lilly and Company discovers, develops, and markets human pharmaceuticals in the United States, Europe, China, Japan, and internationally. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity. It also provides oncology products, including Alimta, Cyramza, Erbitux, Ja... [Read more]
Financial Performance
In 2024, Eli Lilly and Company's revenue was $45.04 billion, an increase of 32.00% compared to the previous year's $34.12 billion. Earnings were $10.59 billion, an increase of 102.08%.
Financial numbers in USD Financial StatementsNews
Eli Lilly (LLY) Partners with Schrodinger to Enhance Drug Discovery
Eli Lilly (LLY) Partners with Schrodinger to Enhance Drug Discovery
Schrodinger to offer Eli Lilly's AI drug discovery platform on its software
Schrodinger said on Friday it is collaborating with Eli Lilly to offer the pharmaceutical major's AI-based platform, TuneLab, on its drug designing software.
Eli Lilly and JD.com have been highlighted as Zacks Bull and Bear of the Day
Eli Lilly's obesity drugs Mounjaro and Zepbound are driving explosive revenue growth, strengthening its dominance as demand accelerates worldwide.
Bull of the Day: Eli Lilly (LLY)
Eli Lilly has solidified itself as a global pharma titan. With leading drugs and a massive obesity market, Lilly is poised to be a juggernaut for years to come.
Eli Lilly: TOGETHER-PsA Study Meets Primary Endpoint At 36 Weeks
(RTTNews) - Eli Lilly and Company (LLY) announced positive topline results from the TOGETHER-PsA open-label Phase 3b trial evaluating the concomitant use of Taltz and Zepbound compared to Taltz alone ...
Ventyx Biosciences Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Ventyx Biosciences, Inc. - VTYX
NEW YORK and NEW ORLEANS, Jan. 8, 2026 /PRNewswire/ -- Former Attorney General of Louisiana Charles C. Foti, Jr., Esq.
Eli Lilly's (LLY) Taltz and Zepbound Show Positive Results in Psoriatic Arthritis Trial
Eli Lilly's (LLY) Taltz and Zepbound Show Positive Results in Psoriatic Arthritis Trial
Eli Lilly (LLY) Reports Positive Results with Psoriatic Arthritis Treatment
Eli Lilly (LLY) Reports Positive Results with Psoriatic Arthritis Treatment
Lilly's Zepbound plus Taltz boosts arthritis relief, weight loss in late-stage trial
Eli Lilly said on Thursday a late-stage trial showed its weight-loss drug Zepbound, used with its psoriatic arthritis treatment Taltz, improved arthritis symptoms and drove weight loss better than Tal...
Eli Lilly (LLY) Poised for Aggressive M&A Amid Biopharma Surge
Eli Lilly (LLY) Poised for Aggressive M&A Amid Biopharma Surge
Insiders Bullish on Certain Holdings of OZEM
A look at the weighted underlying holdings of the Roundhill GLP-1 & Weight Loss ETF (OZEM) shows an impressive 17.8% of holdings on a weighted basis have experienced insider buying within the past six...
Pharma stocks are set to take off this year, says UBS' Michael Yee
Michael Yee, global head of biotech research at UBS, joins CNBC's ‘Squawk on the Street' to explain why he is bullish on biopharma stocks this year, the pharma M&A outlook, and more.
Is LLY's Ventyx Deal Another Attempt at Diversification Beyond GLP-1?
Eli Lilly ramps up M&A activity, adding Ventyx and other assets to diversify beyond obesity as competition in the GLP-1 space intensifies.
Eli Lilly (LLY) Achieves Significant Milestone in Collaboration with ProQR
Eli Lilly (LLY) Achieves Significant Milestone in Collaboration with ProQR
Best Growth Stocks to Buy for January 8th
MU, LLY and SKIL made it to the Zacks Rank #1 (Strong Buy) growth stocks list on January 8th, 2026.
Eli Lilly in Advanced Talks to Buy Ventyx for About $1 Billion
Eli Lilly in Advanced Talks to Buy Ventyx for About $1 Billion
Eli Lilly Confirms Plan To Buy Ventyx Biosciences In $1.2 Billion Deal
Eli Lilly confirmed its $1.2 billion plan late Wednesday to acquire Ventyx Biosciences. Ventyx stock ran up nearly 40% during regular trades.
Eli Lilly (LLY) Acquires Ventyx Biosciences for $1.2 Billion
Eli Lilly (LLY) Acquires Ventyx Biosciences for $1.2 Billion
Eli Lilly confirms deal to buy Ventyx Biosciences for $14 a share
Eli Lilly (LLY) to Acquire Ventyx Biosciences in $1.2 Billion Deal
Eli Lilly (LLY) to Acquire Ventyx Biosciences in $1.2 Billion Deal
Eli Lilly (LLY) Set to Acquire Ventyx Biosciences in Cash Deal
Eli Lilly (LLY) Set to Acquire Ventyx Biosciences in Cash Deal
Dow Jones Futures: Stock Market Fades From Highs; Eli Lilly, Google Lead New Buys
The S&P 500 and Dow reversed from highs Wednesday, while the Nasdaq pared gains. Eli Lilly and Google flashed buy signals.
Eli Lilly to buy Ventyx Biosciences in $1.2 billion deal
Eli Lilly will buy Ventyx Biosciences in an all-cash deal worth $1.2 billion, the companies said on Wednesday, marking the Zepbound maker's latest push to expand beyond its blockbuster diabetes and we...
Lilly to acquire Ventyx Biosciences to advance oral therapies targeting inflammatory-mediated diseases
Ventyx's clinical pipeline includes multiple small molecules with potential for oral therapies addressing chronic inflammation Acquisition builds on Lilly's established capabilities in inflammatory-me...
Eli Lilly (LLY) Partners with InduPro for Oncology Innovations
Eli Lilly (LLY) Partners with InduPro for Oncology Innovations